Mizuho Securities analyst Difei Yang maintained a Hold rating on Abeona Therapeutics (ABEO) today and set a price target of $4.00. The company’s shares closed last Monday at $2.33, close to its 52-week low of $1.46.
According to TipRanks.com, Yang is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.0% and a 32.8% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abeona Therapeutics with a $9.50 average price target, representing a 313.0% upside. In a report released yesterday, JonesTrading also reiterated a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.55 and a one-year low of $1.46. Currently, Abeona Therapeutics has an average volume of 971K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
